Why does IHC remain so popular for CDx development?
The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development.
New China operation
December 30th was an exciting day for NeoGenomics as we got the keys to our new facility in Suzhou, China.
CRO and Clinical Reference Laboratory Commercial Incentives
One of the challenges developing a companion diagnostic is creating a test that runs well in both clinical trials, and following regulatory approval, clinical testing laboratories Unfortunately, in
Oncology Clinical Trials During a Pandemic
2020 has really been a year that doesn’t quit, hasn’t it?
It’s a Great Clinical Trial Assay
While there are many great tools and technologies available to support drug development, the number of platforms used for CDx development remains very limited.
Is It Validated?
NeoGenomics has a menu of >600 assays across many different technologies and approaches.
Liquid Biopsy Testing for PIK3CA Mutation
For years, researchers have looked into liquid biopsy as a potentially useful tool to help Health Care Providers assess a patient’s response to treatment, monitor cancer recurrence and even detect
A spotlight on CDx development
NeoGenomics will share several posts focusing on CDx development.